AADAT and in situ carcinoma: After confirming that sub-chronic administration of CIS induced alterations in brain KYNA levels, our next step was to modulate KYNA using NAC—an inhibitor of KATII- to determine whether KYNA is implicated in the cognitive impairment induced by this chemotherapeutic agent.